



HEPATIC ENCEPHALOPATHY;

TO COMPARE THE EFFICACY OF LACTULOSE ALONE AND LACTULOSE WITH RIFAXAMIN IN PATIENTS OF HEPATIC ENCEPHALOPATHY.

1. MBBS, M.Phil (Pharmacology)
Assistant Professor of
Pharmacology,
Sheikh Zayed Medical College/
Hospital, Rahim Yar Khan.
2. MBBS, MD, FCPS (Medicine)
Senior Registrar (Medical Unit-II)
Department of Medicine,
Sheikh Zayed Medical College/
Hospital, Rahim Yar Khan.
3. MBBS, FCPS (Gynae & Obs)
Senior Demonstrator
Department of Pharmacology
& Therapeutics, Sheikh Zayed
Medical College/Hospital, Rahim
Yar Khan.
4. MBBS, M.Phil (Hematology)
Assistant Professor
Department of Pathology
Sheikh Zayed Medical College/
Hospital, Rahim Yar Khan.

Correspondence Address:

Dr. Mazhar Hussain
Assistant Professor of Pharmacology
& Therapeutics
Sheikh Zayed Medical College
Rahim Yar Khan
Address: House no 214/c
Satellite Town, Rahim Yar Khan
mazharhussain214@gmail.com

Article received on:

16/02/2017

Accepted for publication:

15/05/2017

Received after proof reading:

03/07/2017

INTRODUCTION

Cirrhosis is described as end stage disease resulting due to progressive liver damage. This can be due to various etiologies comprising hepatitis (due to various viruses), alcohol, drugs, toxins, hereditary disorders etc. This end up in architectural distortion and due to fibrosis and damage, it interferes with the normal liver functioning. This is an irreversible process and the ultimate recovery can be achieved by transplantation only. Patients present with wide range of symptoms depending upon the type of complication developed in each case including ascities, GI bleeding, hepato-renal syndrome, encephalopathy etc. Cirrhosis had led to more 25 thousand deaths in US in a single year in 2000. Hepatic encephalopathy is a well reported and dreadful complication of cirrhosis.¹⁻²

Mazhar Hussain¹, Habib-Ur- Rehman², Lubna Akhtar³, Muhammad Bilal Ghafoor⁴

ABSTRACT... Background: Hepatic encephalopathy is one of the fatal complications of liver cirrhosis in clinical setting. A number of drugs with varied response have been tried up till now. **Objectives:** To compare the efficacy of lactulose alone and in combination with rifaxamin in cases with hepatic encephalopathy. **Study Design:** Randomized control trail. **Setting:** Sheikh Zayed Hospital (SZH) Rahim Yar Khan (RYK). **Period:** January 2015 to October 2015. **Patients and Methods:** 120 cases of liver cirrhosis with encephalopathy were randomized into different grades according to West Haven's criteria. These cases were then equally divided into group A and B. Group A was treated with lactulose alone while group B was treated with lactulose plus rifaxamin with their standard doses. The cases were assessed for their improvement in symptoms on West Haven's scale and the cases with complete resolution of symptoms were labeled as cured. The mortality benefit was also noted. **Results:** The mean age was 43.24 ± 8.34 years and mean duration of symptoms was 3.45 ± 0.8 days. There was no significant difference in terms of child pugh score in both groups with $p = 0.69$. There was also no significant difference in both groups in terms of grades of encephalopathy ($p = 0.21$). However there was significant better efficacy and decreased mortality in group B as compared to A with p values of 0.02 and 0.03 respectively. **Conclusion:** Lactulose combined with rifaxamin has significant improvement in encephalopathy as well as in reducing mortality in comparison with lactulose alone

Key words: Hepatic encephalopathy, Lactulose, Rifaxamin. West Haven criteria.

Article Citation: Hussain M, Habib-ur-Rehman, Akhbar K, Ghafoor MB. Hepatic encephalopathy; to compare the efficacy of lactulose alone and lactulose with rifaxamin in patients of hepatic encephalopathy. Professional Med J 2017;24(7):947-951. DOI: 10.17957/TPMJ/17.3892

There are multiple theories regarding its development. The most popular is the ammonia theory which describes that there is increased production of ammonia in such cases by gut flora that surpasses the detoxification capabilities of the liver and cross the blood brain barrier and affect the brain in multiple ways. Secondly there is another theory regarding imbalance between the ratios of plasma aromatase amino acid to branched chain amino acids. This leads to more of the aromatase amino acid resulting more of such neurotransmitters that can interfere with normal functioning. The other one is GABA receptor inhibition at the post synaptic membrane.³⁻⁶

Patients can present with variety of symptoms, among which the diurnal sleep variation is the primary pattern. Later on asterixia (flapping tremors over outstretched hands), bradykinesia,

hyper reflexia on deep tendon reflex and transient de-cerebrate posturing, alerted mental status and irrelevant talks, fits, coma and focal neurological deficits are the other complications to develop.⁷⁻⁸

A number of treatments have been tried either singly or in combination of two or more and in comparison with placebos as well. These included lactulose, lactitol, anemas, dietary restriction of dietary protein and oral antibiotics in the form of metronidazole, neomycin, vancomycin, rifaximin, probiotics, amino acids and multiple minerals have been tried. They have shown different degree of effectiveness. However metronidazole, lactulose and enema are the most commonly used. Rifaximin is an oral antibiotic which is not absorbed in the gut and has shown good efficacies in altering gut flora.⁹⁻¹²

PATIENTS AND METHODS

It was a randomized control trial conducted at Sheikh Zayed Hospital. Rahim Yar Khan from January 2015 to October 2015. In this study total 120 cases of liver cirrhosis were identified and selected. Liver cirrhosis was confirmed by signs and symptoms and on USG abdomen with shrunken size and dilated portal vein with splenomegaly. The encephalopathy was grades according to West Haven's criteria. The cases with hepatocellular carcinoma, active alcoholics, psychiatric patients and those with encephalopathies due to any other cause and with renal failure were excluded. These cases were then admitted at the medical department of Sheikh Zayed Hospital. RYK and their all baseline investigations were sent including complete blood examination, hepatitis B and C serology, liver function tests, PT, APTT and renal function tests. The cases fulfilling the inclusion criteria were then divided into two equal groups with 60 cases in each group via shield opaque method. Then group A was treated with lactulose alone and group B was with lactulose plus rifaximin with their standard doses. The cases were then followed and assessed for their improvement in symptoms and assessed on West Haven scale and the cases with complete resolution of symptoms were labeled as cured. The mortality

benefit was also noted.

West Haven criteria

The cases with hepatic encephalopathy were divided into following four groups according to these criteria;

- Grade 1; Trivial lack of awareness; euphoria or anxiety; shortened attention span; impaired performance of addition or subtraction
- Grade 2; Lethargy or apathy; minimal disorientation for time or place; subtle personality change; inappropriate behavior
- Grade 3; Somnolence to semi-stupor, but responsive to verbal stimuli; confusion; gross disorientation
- Grade 4; Coma

STATISTICAL ANALYSIS

A sample of 60 cases in each group was selected. The data was entered and analyzed on SPSS version 20.0. The categorical data was checked for frequencies and percentages. For continuous data, independent sample t test and for categorical data chi square test was used to compare the two groups. Both groups were also compared for efficacy and mortality benefit. Post stratification chi square test was applied and p value of ≤ 0.05 was considered as significant.

RESULTS

In this study there were 120 cases out of which 91 had hepatitis C, 20 had hepatitis B while 9 had both B & C. The mean age was 43.24 ± 8.34 years and mean duration of symptoms was 3.45 ± 0.8 days. There were 60 cases in each group. Group A had 29 (48.33%) males and 31 (51.67%) females while Group B had 34 (48.33%) males and 26 (51.67%) females. There was no significant difference in terms of child pugh score in both groups with maximum cases was in Class C in both groups with $p = 0.69$ (Table-I). There was also no significant difference in both groups in terms of grades of encephalopathy ($p = 0.21$) as shown in Table-II. However there was significant better efficacy and decreased mortality in group B as compared to A with p values of 0.02 and 0.03 respectively (Table-III).

Child pugh score	Group A (n= 60)	Group B (n= 60)	
A	2(3.33%)	1(1.67%)	p= 0.69
B	19 (31.67%)	22 (36.67%)	
C	39 (65%)	37 (61.67%)	

Table-I. Distribution of patients according to child pugh score

Grade	Treatment group		p value
	Group A	Group B	
I	4 (6.67%)	3 (5%)	p= 0.21
II	8 (13.33%)	6 (10%)	
III	20 (33.33%)	18 (30%)	
IV	28 (46.67%)	33 (55%)	

Table-II. Encephalopathy grading between two groups

Variable	Group A (n= 60)	Group B (n= 60)	p value
Efficacy	31 (51.67%)	42 (70%)	0.02
Death	29 (48.33%)	18 (30%)	0.03

Table-III. Efficacy and mortality comparison.

DISCUSSION

Liver cirrhosis especially due to hepatitis B and C is a great health concern and their number is on the rise in developing countries where there are lesser health facilities and poor awareness. This leads to progression of disease and then complications like hepatic encephalopathy have been observed which if not managed aggressively can be fatal. A number of pharmacological and non pharmacological maneuvers have been considered to avoid this with different degree of success.

In this study the efficacy with lactulose alone was seen in 31 (51.67%) cases as compared to higher success with the combination of lactulose and rifaxamin affecting 42 (70%) of cases with significant p value of 0.02. This was also observed by many other studies as well that found this combination as more effective.¹³⁻¹⁵ In a study done by Palik YH et al significant improvement was seen in cases with combined therapy.¹³ The reason for higher success of combined therapy as compared to alone can be due to additive effects of these drugs. Lactulose is a polysaccharide which is non absorbable and it works as an

osmotic laxative and it also interferes with the action of the gut flora and resulting in alteration of the pH in the gut. It also enhances the clearance of ammonia from the gut by converting it from diffuse able form to non diffusible ammonium form. On the other hand rifaxamin is an antibiotic which is not absorbed through the gut and it helps creating the balance between the gut flora.¹⁶⁻¹⁷ While in another study done by Als-Nielsen B et al, the lactulose was compared with placebo and there was even no significant difference was seen as well.¹⁸

The mortality was also better reduced by the combination therapy as compared to alone where it was seen in 29 (48.33%) cases with lactulose only and 18 (30%) cases with combination therapy with significant difference of 0.03. Similar was observed by other studies.^{14,19-20} According to a study by Irimia R et al the rifaxamin only too was superior to lactulose in encephalopathy.¹⁹ A study done by Haq MIU et al also revealed significant improvement in mortality where out of their both groups of 80 patients 33 died with lactulose alone as compared to 17 only with combination therapy.²⁰ This also can be explained the same pathophysiology and mechanism of action of the drugs. The cases with better and early clearance of the gut also had lesser ammonia to cause encephalopathy and the other causes like aspiration pneumonia, nutritional deficiencies and other complications like bed sore sepsis etc has also lesser chances to develop and that's why the mortality benefit was higher.

There were few limitations of this study as the data was collected only for complete resolution and not for betterment in grade of encephalopathy and neither was assessed for duration taken to cure.


CONCLUSION

Hepatic encephalopathy is a fatal complication. Lactulose combined with rifaxamin has significant improvement in encephalopathy as well as in reducing mortality.

Copyright© 15 May, 2017.

REFERENCES

1. Liao WC, Hou MC, Chang CJ. **Potential precipitating factors of esophageal variceal bleeding: a case-control study.** *Am J Gastroenterol.* 2011; 106:96-99.
2. Mumtaz K, Ahmed US, Abid S. **Precipitating factors and the outcome of hepatic encephalopathy in liver cirrhosis.** *J CollPhysSurg Pak.* 2010; 20:514-20.
3. Sundaram V, Shaikh OS. **Hepatic encephalopathy: pathophysiology and emerging therapies.** *Med Clin North Am.* 2009; 93:819-24.
4. O'Beirne JP, Chouhan M, Hughes RD. **The role of infection and inflammation in the pathogenesis of hepatic encephalopathy and cerebral edema in acute liver failure.** *Nat ClinPractGastroenterolHepatol.* 2006; 3:118-24.
5. Strauss G, Hansen BA, Kirkegaard P. **Liver function, cerebral blood flow autoregulation, and hepatic encephalopathy in fulminant hepatic failure.** *Hepatology.* 1997; 25:837-42.
6. Larsen FS, Knudsen GM, Hansen BA. **Pathophysiological changes in cerebral circulation, oxidative metabolism and blood-brain barrier in patients with acute liver failure.** Tailored cerebral oxygen utilization. *J Hepatol.* 1997; 27:231-38.
7. Ferenci P, Lockwood A, Mullen K. **Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.** *Hepatology.* 2002; 35:716-22.
8. Cadranet JF, Lebiez E, Di Martino V. **Focal neurological signs in hepatic encephalopathy in cirrhotic patients: an underestimated entity?** *Am J Gastroenterol.* 2001; 96:515-22.
9. Sharma BC, Sharma P, Agrawal A, Sarin SK. **Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.** *Gastroenterology* 2009; 137:885-88.
10. Als-Nielsen B, Gluud LL, Gluud C. **Nonabsorbable disaccharides for hepatic encephalopathy.** *Cochrane Database Syst Rev* 2004; CD003044.
11. Les I, Doval E, García-Martínez R. **Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study.** *Am J Gastroenterol.* 2011; 106:1081-88.
12. Koretz RL, Avenell A, Lipman TO. **Nutritional support for liver disease.** *Cochrane Database Syst Rev* 2012; 5:CD008344.
13. Paik YH, Lee KS, Han KH. **Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.** *Yonsei Med J.* 2005; 46:399-407.
14. Bucci L, Palmieri GC. **Double blind, double dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy.** *Curr Med Res Opin.* 1993; 13:109-18.
15. Mas A, Rodés J, Sunyer L. **Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.** *J Hepatol.* 2003; 38:51-8.
16. Ojetti V, Lauritano EC, Barbaro F. **Rifaximin pharmacology and clinical implication.** *Expert Opin Drug Meta Toxicol.* 2009; 5:675-82.
17. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. **A randomized, double blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.** *Am J Gastroenterol.* 2013; 108: (9):1458-63.
18. Als-Nielsen B, Gluud LL, Gluud C. **Non absorbable disaccharides for hepatic encephalopathy: systemic review of randomised trials.** *BMJ.* 2004; 328:1046-51.
19. Irimia R1, Trifan A. **Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hospitalizations in cirrhosis.** *Rev Med ChirSoc Med Nat Iasi.* 2012; 16(4):1021-27.
20. Haq MIU, Sallm A, Afzal MS, Malik K, Amin J, Butt AK. **Comparison of rifaximin and lactulose with lactulose alone in the treatment of acute hepatic encephalopathy in patients with liver cirrhosis.** *Proceedings ShZayed Post Grad Med Inst.* 2014; 28(2):115-19.



*“If you desire to make a difference in the world,
you must be different from the world.”*

Unknown

AUTHORSHIP AND CONTRIBUTION DECLARATION

Sr. #	Author-s Full Name	Contribution to the paper	Author=s Signature
1	Dr. Mazhar Hussain	Conceived the idea, manuscript review and tatistical analysis.	
2	Dr. Habib-Ur- Rehman	Designed the study, preparing the manuscript and data analysis.	
3	Dr. Lubna Akhtar	Search the literature, collected the clinical data, manuscript editing and drafting of the manuscript.	
4	Dr. Muhammad Bilal Ghafoor	Final editing, plagiarism and drafting of manuscript.	